These findings suggest that ERBB2 overexpression activates oncogenic signaling pathways, such as PI3K/AKT/mTOR and MAPK/ERK, promoting tumor proliferation and survival, particularly in patients with metabolic comorbidities. Here, MTOR is linked to neoplasm.